Truist Financial Lowers Genmab A/S (NASDAQ:GMAB) Price Target to $45.00

Genmab A/S (NASDAQ:GMAB) had its price target reduced by analysts at Truist Financial from $50.00 to $45.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price points to a potential upside of 122.66% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. Finally, William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and an average price target of $41.33.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $20.21 on Tuesday. The stock has a market capitalization of $13.37 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 2.65 and a beta of 0.98. The company has a 50 day moving average price of $21.28 and a 200 day moving average price of $22.52. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $31.88.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, sell-side analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of large investors have recently bought and sold shares of GMAB. Deep Track Capital LP bought a new stake in shares of Genmab A/S during the 4th quarter worth approximately $41,740,000. Renaissance Technologies LLC increased its stake in Genmab A/S by 7.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock worth $40,199,000 after acquiring an additional 139,722 shares during the period. Two Sigma Investments LP grew its stake in Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after buying an additional 938,455 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in shares of Genmab A/S by 168.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock valued at $34,509,000 after purchasing an additional 1,038,400 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in Genmab A/S by 18.0% during the fourth quarter. First Trust Advisors LP now owns 1,644,288 shares of the company’s stock worth $34,316,000 after acquiring an additional 251,241 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.